Epilepsy in patients with advanced Fukuyama congenital muscular dystrophy

Ryoko Kuwayama1, Yasuhiro Suzuki2, Masanori Nishikawa3

  • 1Department of Pediatric Neurology, Osaka Women's and Children's Hospital, Japan; Department of Pediatrics, Graduate School of Medicine, Osaka University, Japan.

Brain & Development
|July 30, 2020
PubMed

Insights

Epilepsy can develop in Fukuyama congenital muscular dystrophy (FCMD) patients after childhood, with seizures often persisting into adulthood. Clinicians should monitor for late-onset seizures, particularly in advanced disease stages.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Fukuyama congenital muscular dystrophy (FCMD) is a genetic disorder characterized by congenital muscular dystrophy and brain malformation.
  • While childhood seizures are common in FCMD, long-term epilepsy patterns remain understudied.

Purpose of the Study:

  • To investigate the long-term clinical course and characteristics of epilepsy in patients with FCMD.
  • To understand the progression and management challenges of late-onset seizures in this population.

Main Methods:

  • Retrospective review of medical records from nine FCMD patients diagnosed between 1981 and 2019.
  • Analysis of 75 EEG recordings and clinical seizure data over extended follow-up periods (mean 18.4 years).

Main Results:

  • Epileptic seizures were observed in six of nine patients, with five developing epilepsy between ages 13-22.
  • Focal impaired awareness seizures were most common; status epilepticus occurred in four patients after adolescence.
  • Seizures were frequently uncontrolled (5/6 patients) at the last evaluation, with reduced convulsive activity in advanced disease.

Conclusions:

  • Epileptic seizures can manifest after childhood in FCMD patients, irrespective of brain malformation.
  • Increased vigilance for late-onset epilepsy is crucial, especially in FCMD patients with significant muscle weakness.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
768
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
499